Orthofix Med (OFIX) Stock News

Orthofix (NASDAQ:OFIX) reported its Q2 2025 financial results with pro forma net sales of $200.7 million, representing a 4% increase on a constant currency basis year-over-year. The company posted a net loss of $(14.1) million, or $(0.36) per share.

Key highlights include U.S. Spine Fixation growth of 5%, Bone Growth Therapies sales of $62.6 million (up 6%), and Global Orthopedics sales of $33.3 million with 5% constant currency growth. The company achieved its sixth consecutive quarter of adjusted EBITDA margin expansion, with pro forma adjusted EBITDA of $20.6 million and positive free cash flow of $4.5 million.

Orthofix reaffirmed its full-year 2025 guidance, expecting pro forma net sales between $808-816 million and adjusted EBITDA of $82-86 million.

Orthofix Medical (NASDAQ:OFIX), a global medical technology company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will deliver a presentation on Wednesday, August 13, 2025, at 9:00 am Eastern Time.

Investors can access both the live and archived versions of the presentation through the "Events & Presentations" section on Orthofix's Investor Relations website at ir.orthofix.com. The company also maintains regular investor updates on its main website at www.orthofix.com.

Orthofix Medical (NASDAQ:OFIX), a global medical technology company, will release its second quarter 2025 financial results on Tuesday, August 5, 2025, before the market opens. The company will host a conference call and webcast at 8:30 AM ET on the same day.

Investors can join the conference call by dialing (888) 596-4144 in the U.S. or (646) 968-2525 internationally, using conference ID 4830464. The webcast and earnings release will be available on the company's investor relations website.

Orthofix Medical Inc. (NASDAQ:OFIX) has announced the global commercial launch of the TrueLok Elevate Transverse Bone Transport (TBT) System, the first FDA-cleared device in the U.S. for TBT procedures aimed at limb preservation. The system targets bony and soft tissue deformities, particularly diabetic ulcers. With diabetes projected to affect 700 million people globally by 2045 and over 160,000 annual diabetic-related amputations in the U.S., the market opportunity is estimated at $1.2 billion. The device has shown promising results during limited market release with over 130 procedures completed globally. Notably, diabetic foot ulcer patients who undergo amputation face a 57% five-year mortality rate and lifetime healthcare costs exceeding $640,000, making TrueLok Elevate a potentially cost-effective limb-saving solution.

Orthofix Medical Inc. (NASDAQ:OFIX) reported its Q1 2025 financial results with net sales of $193.6 million, representing a 2.7% increase year-over-year. The company posted a net loss of $(53.1) million, or $(1.35) per share. Notable performance includes Bone Growth Therapies sales growth of 5%, Global Orthopedics achieving 11% constant currency growth, and U.S. Spine Fixation growth of 4%.

The company updated its 2025 guidance, now expecting net sales between $808-816 million, while reaffirming non-GAAP adjusted EBITDA guidance of $82-86 million. Pro forma adjusted EBITDA for Q1 was $11.4 million, showing a 200 basis points margin expansion. The company is executing a commercial channel optimization strategy, though this has caused some softness in Biologics and Spine Fixation segments.

Cash position stood at $60.5 million as of March 31, 2025, down from $85.7 million in December 2024, primarily due to annual bonus payments and commissions.

Orthofix Medical (NASDAQ:OFIX) has scheduled the release of its first quarter 2025 financial results for Tuesday, May 6, 2025, before the market opens. The company will host a conference call and webcast at 8:30 am Eastern Time on the same day to discuss the results.

Participants can join the conference call by dialing (888) 596-4144 in the U.S. and (646) 968-2525 from other locations, using conference ID 7524113. The webcast and earnings release will be available at ir.Orthofix.com.

Orthofix Medical Inc. (NASDAQ:OFIX) has received both FDA 510(k) clearance and European CE Mark for its TrueLok™ Elevate Transverse Bone Transport (TBT) System, marking a significant advancement in limb preservation treatment.

The system, currently in market release in the U.S. and select international markets, addresses bony and soft tissue deformities, including diabetic foot ulcers and nonhealing wounds. It is the first FDA-cleared dedicated system for TBT procedures, enabling surgeons to create and gradually distract bone segments in the tibia.

This innovation targets a $1.2 billion market opportunity, addressing the over 160,000 annual diabetic-related amputations in the U.S. Studies show patients with diabetic foot ulcers who undergo amputation face a 57% five-year mortality rate and lifetime healthcare costs exceeding $640,000 for amputation-related care.

Orthofix Medical (NASDAQ:OFIX) has appointed Vickie Capps to its Board of Directors, effective March 11, 2025. This strategic addition expands the board to ten members, bringing diverse expertise in global business operations, strategic development, and corporate finance.

Capps, a Certified Public Accountant with a B.S. in business administration from San Diego State University, brings significant experience from her role as former CFO of DJO Global, Inc. She currently serves on multiple boards, including Amedisys, Inc., Janux Therapeutics, Inc., Enable Injections, Inc., and Breg, Inc. She is also a member of the Senior Advisory Board of Consonance Capital Partners.

The appointment aligns with Orthofix's strategic transformation aimed at delivering profitable growth and sustainable shareholder value in the medical technology sector, focusing on musculoskeletal pathologies.

Orthofix Medical (NASDAQ:OFIX) has announced its participation in the 37th Annual Roth Conference in Dana Point, CA. The company's management team is scheduled to deliver a presentation on Monday, March 17, 2025, at 8:00 AM Pacific Time.

Investors and interested parties can access both the live and archived versions of the presentation through the 'Events & Presentations' section on Orthofix's investor relations website at ir.orthofix.com. The company also maintains regular updates of important investor information in the 'Investors' section of their corporate website at www.orthofix.com.